Extranodal Marginal Zone Lymphoma research hub

A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)

This study is looking at a new way to treat a type of cancer called MALT lymphoma. It combines two medicines, chlorambucil and rituximab, given in a drip and under the skin, to see how well they work together and if they cause many side effects.